


## Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

### Listing of Claims

1. (Withdrawn) Compounds of formula I :



**I**

wherein


R<sup>1</sup> = H, or C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR<sup>3</sup>, -C(O)OR<sup>3</sup>, -C(O)R<sup>3</sup>, -CH<sub>2</sub>C(O)OR<sup>3</sup>, -CH<sub>2</sub>C(O)NHR<sup>3</sup>, where R<sup>3</sup> is H or C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, or alkenyl;

R<sup>2</sup> = C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


X<sup>1</sup> = NHR<sup>4</sup>, where R<sup>4</sup> is H, C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R<sup>4</sup> group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R<sup>4</sup> group further optionally containing one or more halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein R<sup>1</sup> is H, or C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or =CH<sub>2</sub>.


3. (Withdrawn) The compounds of claim 2, wherein  $R^1$  is  $-CH_3$  or  $=CH_2$ .
4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:



5. (Withdrawn) The compounds of claim 1, wherein  $R^4$  is  $-CH_2C(O)OR^5$  or  $-CH_2C(O)NHR^5$ , where  $R^5$  is H,  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



## II

wherein


$R^6 = H$ , or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^8$ ,  $-C(O)R^8$ ,  $-CH_2C(O)OR^8$ ,  $-CH_2C(O)NHR^8$ , where  $R^8$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^7 = C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^2 = NHR^9$ , where  $R^9$  is H,  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^9$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^9$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^6$  is  $-CH_3$ , and  $R^7$  is  $n-C_{13}H_{27}$ ,  $X^2$  is not  $-NHC_2H_5$ .

8. (Withdrawn) The compounds of claim 7, wherein  $R^6$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
9. (Withdrawn) The compounds of claim 8, wherein  $R^6$  is  $-CH_3$ .
10. (Withdrawn) The compounds of claim 7, wherein  $R^9$  is  $-CH_2C(O)OR^{10}$  or  $-CH_2C(O)NHR^{10}$ , where  $R^{10}$  is H,  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
11. (Withdrawn) Compounds of formula IV:



**IV**

wherein

$R^{16}$  = H, or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{18}$ ,  $-C(O)R^{18}$ ,  $-CH_2C(O)OR^{18}$ ,  $-CH_2C(O)NHR^{18}$ , where  $R^{18}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{17}$  =  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


$X^4$  =  $OR^{19}$ , where  $R^{19}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{19}$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $R^{19}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{16}$  is  $-CH_3$  and  $R^{19}$  is  $-CH_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl,  $-nC_3H_7$ ,  $-nC_5H_{11}$ ,  $-nC_{13}H_{27}$ , and with the further proviso that when  $R^{16}$  is H and  $R^{19}$  is  $-CH_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl or  $-CH_3$ , and when  $R^{16}$  is H and  $R^{19}$  is  $-CH_2CH_3$ , then  $R^{17}$  is not  $-iC_3H_7$ , or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein  $R^{16}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein  $R^{16}$  is  $-CH_3$ .

14. (Withdrawn) The compounds of claim 11, wherein  $R^{19}$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{20}$  or  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{20}$ , where  $R^{20}$  is  $\text{C}_1\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
15. (Currently Amended) Compounds of formula V:




wherein

$R^{21}$  = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=\text{CHR}^{23}$ ,  $-\text{C}(\text{O})\text{OR}^{23}$   
 $-\text{C}(\text{O})\text{R}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{23}$ , where  $R^{23}$  is H or  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, or alkenyl, except when  $R^{21}$  is  $=\text{CHR}^{23}$ ,  $R^{23}$  is not H;

$R^{22}$  =  ~~$\text{C}_2\text{-C}_{20}$~~   $\text{C}_7\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, ; arylalkyl, or alkylaryl;

with the proviso that when  $R^{21}$  is  $-\text{COOH}$ , then  $R^{22}$  is not  $-\text{CH}_3$ ,  $-\text{nC}_5\text{H}_{11}$ , or  $\text{C}_{13}\text{H}_{27}$  and with the further proviso that when  $R^{21}$  is  $-\text{CH}_2\text{COOH}$ , then  $R^{22}$  is not  $-\text{CH}_2\text{CH}_3$ , or  $-\text{iC}_5\text{H}_{11}$ .

16. (Previously Presented) The compounds of claim 15, wherein  $R^{21}$  is cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
17. (Cancelled)
18. (Withdrawn) Compounds of formula VI:



**VI**

wherein:

$R^{24} = C_2-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{26}$ ,


$-C(O)R^{26}$ ,  $-CH_2C(O)OR^{26}$ ,  $-CH_2C(O)NHR^{26}$ , where  $R^{26}$  is H or  $C_1-C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{25} = C_1-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when  $R^{24}$  is  $-COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-nC_5H_{11}$ , or  $C_{13}H_{27}$ , and with the further proviso that when  $R^{24}$  is  $-CH_2COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

19. (Withdrawn) The compounds of claim 18, wherein  $R^{24}$  is  $C_2-C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Previously Presented) Compounds of formula VII:




**VII**

wherein

$R^{27} = C_{16}\text{-}C_{20}$  alkyl.

21 – 22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



**IX**

$R^{29} = H$ , or  $C_1\text{-}C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{31}$ ,


$-C(O)OR^{31}$ ,  $-C(O)R^{31}$ ,  $-CH_2C(O)OR^{31}$ ,  $-CH_2C(O)NHR^{31}$ , where  $R^{31}$  is  $H$  or  $C_1\text{-}C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{30} = C_1\text{-}C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^5 = -OR^{32}$ , or  $-NHR^{32}$ , where  $R^{32}$  is  $H$ ,  $C_1\text{-}C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{32}$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^{32}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{29}$  is  $=CH_2$ , then  $X^5$  is not  $OH$ .


24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein  $R^{29}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=CH_2$ .
25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein  $R^{29}$  is  $-CH_3$  or  $=CH_2$ .
26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein  $R^{32}$  is  $-CH_2C(O)OR^{33}$  or  $-CH_2C(O)NHR^{33}$ , where  $R^{33}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
27. (Withdrawn) The pharmaceutical compositions of claim 23, where  $R^{29}$  is  $-C_6H_{13}$  or  $-C_8H_{17}$ .
28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.



30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.
31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.
32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.
33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.
34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.
35. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.
36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:



**III**

wherein

$R^{11} = \text{H, or } C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } =\text{CHR}^{13},$   
 $-\text{C}(\text{O})\text{OR}^{13}, -\text{C}(\text{O})\text{R}^{13}, -\text{CH}_2\text{C}(\text{O})\text{OR}^{13}, -\text{CH}_2\text{C}(\text{O})\text{NHR}^{13},$  where  $R^{13}$  is H or  $C_1\text{-}C_{10}$  alkyl,  
 cycloalkyl, or alkenyl;

$R^{12} = C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl} ;$

$X^3 = \text{OR}^{14},$  where  $R^{14}$  is  $C_1\text{-}C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{14}$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $R^{14}$  group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{11}$  is  $C_1\text{-}C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=\text{CH}_2$ .

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein  $R^{11}$  is  $-\text{CH}_3$  or  $=\text{CH}_2$ .


39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{14}$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{15}$  or  $\text{CH}_2\text{C}(\text{O})\text{NHR}^{15}$ , where  $R^{15}$  is  $C_1\text{-}C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.


53. (Withdrawn) The method of claim 51, wherein the compound is:




54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the subject is an animal.
58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
59. (Withdrawn) The method of claim 58, wherein the subject is a human.
60. (Withdrawn) The method of claim 58, wherein the subject is an animal.
61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:




62. (Withdrawn) The method of claim 60, wherein the compound is selected from the group consisting of:




63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 - 65. (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:



68. (Not Entered)

69. (Currently Amended) Compounds according to claim 15, wherein


$\text{R}^{21}$  = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=\text{CHR}^{23}$ ,  $-\text{C}(\text{O})\text{OR}^{23}$ ,  $-\text{C}(\text{O})\text{R}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{23}$ , where  $\text{R}^{23}$  is H or  $\text{C}_1$ - $\text{C}_{10}$  alkyl, cycloalkyl, or alkenyl, except when  $\text{R}^{21}$  is  $=\text{CHR}^{23}$ ,  $\text{R}^{23}$  is not H;

$\text{R}^{22}$  =  $\text{C}_1$ - $\text{C}_{20}$   $\text{C}_7$ - $\text{C}_{20}$  alkyl, cycloalkyl, alkenyl, arylalkyl, or alkylaryl;

with the proviso that when  $\text{R}^{21}$  is  $-\text{COOH}$ , then  $\text{R}^{22}$  is not  $-\text{CH}_3$ ,  $-\text{C}_{13}\text{H}_{27}$  or  $\text{C}_{13}\text{H}_{27}$  and with the further proviso that when  $\text{R}^{21}$  is  $-\text{CH}_2\text{COOH}$ , then  $\text{R}^{22}$  is not  $-\text{CH}_2\text{CH}_3$ , or  $-\text{iC}_3\text{H}_{11}$ .

70. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (Previously Presented) Compounds of formula X:




wherein

$R^{42}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

72. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.

73. (Withdrawn) A method of inhibiting the activity of fatty acid synthase in a cell comprising administering to the cell an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and one or more compounds of formula V:



wherein

$R^{21}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CH-R^{23}$ ,  $-C(O)OR^{23}$

$-C(O)R^{23}$ ,  $-CH_2C(O)OR^{23}$ ,  $-CH_2C(O)NHR^{23}$ , where  $R^{23}$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl; and

$R^{22}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.